Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Exposure to CARDIovascular Risk Assessed by Cardiac Adiposity in oBese adOlescents Eligible to a Residential Long-term Lifestyle Intervention by Diet and eXercise (CARDIBOX) (CARDIBOX)

13 de marzo de 2020 actualizado por: University Hospital, Clermont-Ferrand

Exposure to CARDIovascular Risk Assessed by Cardiac Adiposity in oBese adOlescents Eligible to a Residential Long-term Lifestyle Intervention by Diet and eXercise

The high prevalence of childhood obesity is a major public health issue, worldwide. Childhood obesity is associated with a high risk of cardiovascular events in adulthood, but recent studies also point out the development of cardiovascular complications in childhood or adolescence justifying the need for early detection and appropriate therapeutic management to prevent the development of more severe abnormalities. This project proposes to evaluate the myocardial function in a fine and comprehensive way (longitudinal, circumferential and radial linear deformations, and rotation / torsion mechanics) from the deformation imaging (MRI and high-resolution echocardiography), in obese adolescents following a lifestyle intervention combining diet and physical activity.

Descripción general del estudio

Estado

Desconocido

Descripción detallada

The investigators aim to improve knowledge of the association between epicardial adipose tissue, myocardial lipid content, and left ventricular regional myocardial function.

In this protocol, obese adolescents are recruited undergoing a 3-month lifestyle intervention residential program. Adolescents from the intervention group will be enrolled at the obesity center for the whole school year. The obesity center employs a multidisciplinary team to provide the best weight management care to adolescents during their stay. The weight loss program is an integral part of the obesity center program and fundamentally combines physical activity with a normocaloric diet monitored by a dietician. The physical activity program consists of two training sessions (aerobic and resistance training) per week. Moreover, adolescents will be engaged in two additional sessions per week, consisting in recreational activities such as ball and racquet games, trekking, snowshoeing or swimming.

There will be two measurement time: one at baseline (Day 0) and one at three months after the beginning of the lifestyle intervention (M3). The controls will be evaluated at baseline only.

Statistical analysis will be performed using Stata software (version 13; Stata-Corp, College Station, Tex., USA). All statistical tests will be two-sided and p inferior to 0.05 will be considered significant. Qualitative variables will be described in terms of numbers and proportions. Quantitative variables will be described in terms of numbers, mean standard deviation or median according to statistical distribution (normality studied using Shapiro-Wilk test). Graphic representations will be complete presentations of results. The main analysis will be performed with the Stata software (version 13, StataCorp, College Station). All statistical tests will be carried out at a risk of error of first species α set at 5%. Most of the analysis of the secondary evaluation criteria will be exploratory in nature and may lack power in terms of numbers. As discussed by Feise in 2002,104 the adjustment of the risk of error of 1st species will not be systematically proposed, but case by case in view of clinical considerations and not only statistical (e.g. Sidak correction for the analysis of correlation coefficients).

Qualitative variables will be described in terms of numbers and proportions. Quantitative variables will be described in terms of standard deviation or mean median according to statistical distribution (normality studied using Shapiro-Wilk test). Graphic representations will be complete presentations of results.

Intergroup comparisons will be systematically conducted without adjustment and by adjusting for factors whose distribution could be unbalanced between groups. Patients will be described and compared between groups at inclusion according to the following variables: compliance with eligibility criteria, epidemiological characteristics, clinical characteristics and characteristics of possible treatments. The baseline comparability of the two groups will be assessed on the main characteristics of the participants and potential factors associated with the primary outcome. A possible difference between the two groups on one of these characteristics will be determined according to clinical considerations and not solely statistical ones.

Tipo de estudio

Intervencionista

Inscripción (Anticipado)

50

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Clermont-Ferrand, Francia, 63000
        • CHU de Clermont-Ferrand

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

12 años a 16 años (Niño)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • age between 12 and 16 years old
  • mature (menarche)
  • suitable for physical activity
  • able to give an informative consent
  • affiliated at French insurance company
  • consent from the legal representatives
  • For obese adolescents: BMI greater than the 97th percentile of national curves.
  • For the control group: to be normal-weighted (no obesity if overweight, <85th percentile of national curves).

Exclusion Criteria:

  • Medical or surgical history judged by the investigator as incompatible with the study
  • Drugs that may interfere with the study results
  • Cardiovascular, hepatic, psychiatric, renal, or endocrinological diseases
  • Smoking
  • Alcohol consumption
  • Intense physical activity in competition

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Prevención
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Obese adolescents
BMI greater than the 97th percentile of national curves. Participants will follow a 3-month lifestyle intervention

Adolescents from the intervention group will be enrolled at the obesity center for the whole school year (i.e., 10 months). The physical activity program consists of two training sessions (aerobic and resistance training) per week.

There will be two measurement time: one at baseline (Day 0) and one at three months after the beginning of the lifestyle intervention (M3). The controls will be evaluated at baseline only.

Sin intervención: Control group
to be normal-weighted (no obesity if overweight, <85th percentile of national curves).

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
cardiac ectopic fat deposits
Periodo de tiempo: Month 3
Quantification of cardiac ectopic fat deposits (thickness using echocardiography)
Month 3
cardiac ectopic fat deposits
Periodo de tiempo: Day 0
Quantification of cardiac ectopic fat deposits (thickness using echocardiography)
Day 0
cardiac ectopic fat deposits
Periodo de tiempo: Day 0
Quantification of cardiac ectopic fat deposits (volume using MRI)
Day 0
cardiac ectopic fat deposits
Periodo de tiempo: Month 3
Quantification of cardiac ectopic fat deposits (volume using MRI)
Month 3
cardiac ectopic fat deposits
Periodo de tiempo: Month 3
Quantification of cardiac ectopic fat deposits (myocardial triglyceride content evaluated by MRI)
Month 3
cardiac ectopic fat deposits
Periodo de tiempo: Day 0
Quantification of cardiac ectopic fat deposits (myocardial triglyceride content evaluated by MRI)
Day 0
left myocardial regional function
Periodo de tiempo: Month 3
left myocardial regional function (echocardiography)
Month 3
left myocardial regional function
Periodo de tiempo: Month 3
left myocardial regional function (MRI)
Month 3
left myocardial regional function
Periodo de tiempo: Day 0
left myocardial regional function (echocardiography)
Day 0
left myocardial regional function
Periodo de tiempo: Day 0
left myocardial regional function (MRI)
Day 0

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
macrovascularisation
Periodo de tiempo: Day 0
measure of carotid intima-media thickness (CIMT) using High-resolution B-mode ultrasound
Day 0
macrovascularisation
Periodo de tiempo: Month 3
measure of carotid intima-media thickness (CIMT) using High-resolution B-mode ultrasound
Month 3
microvascularisation
Periodo de tiempo: Month 3
measure of blood flow velocity using laser speckle contrast imaging (LSCI)
Month 3
microvascularisation
Periodo de tiempo: Day 0
measure of blood flow velocity using laser speckle contrast imaging (LSCI)
Day 0
microvascularisation
Periodo de tiempo: Day 0
measure of microvascular perfusion using laser-Doppler flowmetry (LDF)
Day 0
microvascularisation
Periodo de tiempo: Month 3
measure of microvascular perfusion using laser-Doppler flowmetry (LDF)
Month 3
microvascularisation
Periodo de tiempo: Month 3
measure of microvascular perfusion using Iontophoresis procedure
Month 3
microvascularisation
Periodo de tiempo: Day 0
measure of microvascular perfusion using Iontophoresis procedure
Day 0
microvascularisation
Periodo de tiempo: Day 0
measure of microvascular perfusion using flowmotion
Day 0
microvascularisation
Periodo de tiempo: Month 3
measure of microvascular perfusion using flowmotion
Month 3
heart rate variability
Periodo de tiempo: Month 3
measure of heart rate variability using a holter
Month 3
heart rate variability
Periodo de tiempo: Day 0
measure of heart rate variability using a holter
Day 0
skin conductance
Periodo de tiempo: Day 0
measure of skin conductance using Wristband electrodes - Empatica E4
Day 0
skin conductance
Periodo de tiempo: Month 3
measure of skin conductance using Wristband electrodes - Empatica E4
Month 3
Liver steatosis
Periodo de tiempo: Month 3
measure of liver steatosis by MRI
Month 3
Liver steatosis
Periodo de tiempo: Day 0
measure of liver steatosis by MRI
Day 0
Liver steatosis
Periodo de tiempo: Day 0
measure of liver steatosis by fibroscanner (ultrasonic attenuation)
Day 0
Liver steatosis
Periodo de tiempo: Month 3
measure of liver steatosis by fibroscanner (ultrasonic attenuation)
Month 3
Liver steatosis
Periodo de tiempo: month 3
measure of liver steatosis by Aixplorer (Lipersonic Imagine®)
month 3
Liver steatosis
Periodo de tiempo: Day 0
measure of liver steatosis by Aixplorer (Lipersonic Imagine®)
Day 0
Liver fibrosis
Periodo de tiempo: Day 0
measure of liver fibrosis by fibroscanner (liver stiffness)
Day 0
Liver fibrosis
Periodo de tiempo: Month 3
measure of liver fibrosis by fibroscanner (liver stiffness)
Month 3
Liver fibrosis
Periodo de tiempo: Month 3
measure of liver fibrosis by fibrotest (Lipersonic Imagine®)
Month 3
Liver fibrosis
Periodo de tiempo: Day 0
measure of liver fibrosis by fibrotest (Lipersonic Imagine®)
Day 0
blood pressure
Periodo de tiempo: Day0
measure of blood pressure using sphygmomanometer
Day0
blood pressure
Periodo de tiempo: month 3
measure of blood pressure using sphygmomanometer
month 3
Fitness
Periodo de tiempo: Month 3
6-minutes walking test to assess functional capacity at a sub-maximal level, and the effects of exercise training in cardiac and pulmonary patients.
Month 3
Fitness
Periodo de tiempo: Day 0
6-minutes walking test to assess functional capacity at a sub-maximal level, and the effects of exercise training in cardiac and pulmonary patients.
Day 0
muscle mass
Periodo de tiempo: Month 3
measure of muscle mass using impedancemeter
Month 3
fat mass
Periodo de tiempo: Month 3
measure of muscle mass using impedancemeter
Month 3
bone structure
Periodo de tiempo: Month 3
measure of muscle mass using impedancemeter
Month 3
muscle mass
Periodo de tiempo: Day 0
measure of muscle mass using impedancemeter
Day 0
fat mass
Periodo de tiempo: Day 0
measure of muscle mass using impedancemeter
Day 0
bone structure
Periodo de tiempo: Day 0
measure of muscle mass using impedancemeter
Day 0
muscle mass
Periodo de tiempo: Day 0
measure of muscle mass using Densitometry X-ray absorption
Day 0
fat mass
Periodo de tiempo: Day 0
measure of muscle mass using Densitometry X-ray absorption
Day 0
bone structure
Periodo de tiempo: Day 0
measure of muscle mass using Densitometry X-ray absorption
Day 0
muscle mass
Periodo de tiempo: Month 3
measure of muscle mass using Densitometry X-ray absorption
Month 3
fat mass
Periodo de tiempo: Month 3
measure of muscle mass using Densitometry X-ray absorption
Month 3
bone structure
Periodo de tiempo: Month 3
measure of muscle mass using Densitometry X-ray absorption
Month 3
muscle mass
Periodo de tiempo: Month 3
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Month 3
fat mass
Periodo de tiempo: Month 3
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Month 3
bone structure
Periodo de tiempo: Month 3
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Month 3
muscle mass
Periodo de tiempo: Day 0
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Day 0
fat mass
Periodo de tiempo: Day 0
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Day 0
bone structure
Periodo de tiempo: Day 0
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Day 0
muscle mass
Periodo de tiempo: Day 0
measure of muscle mass using Quantitative ultrasounds (QUS)
Day 0
fat mass
Periodo de tiempo: Day 0
measure of muscle mass using Quantitative ultrasounds (QUS)
Day 0
bone structure
Periodo de tiempo: Day 0
measure of muscle mass using Quantitative ultrasounds (QUS)
Day 0
muscle mass
Periodo de tiempo: Month 3
measure of muscle mass using Quantitative ultrasounds (QUS)
Month 3
fat mass
Periodo de tiempo: Month 3
measure of muscle mass using Quantitative ultrasounds (QUS)
Month 3
bone structure
Periodo de tiempo: Month 3
measure of muscle mass using Quantitative ultrasounds (QUS)
Month 3
depression
Periodo de tiempo: Day 0
depression is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always".
Day 0
depression
Periodo de tiempo: Month 3
depression is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always".
Month 3
anxiety
Periodo de tiempo: Day 0
anxiety is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always". It is also evaluated by the State-Trait Anxiety Inventory (STAI) composed by two dimensions, state anxiety and trait anxiety, both evaluated with a 20-items questionnaire on a 4-point scale from "never" to "always"
Day 0
anxiety
Periodo de tiempo: Month 3
anxiety is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always". It is also evaluated by the State-Trait Anxiety Inventory (STAI) composed by two dimensions, state anxiety and trait anxiety, both evaluated with a 20-items questionnaire on a 4-point scale from "never" to "always"
Month 3
General health
Periodo de tiempo: Day 0
general health is assessed by the short form 36 health survey (SF36) composed by 36 items
Day 0
General health
Periodo de tiempo: Month 3
general health is assessed by the short form 36 health survey (SF36) composed by 36 items
Month 3
Stress
Periodo de tiempo: day 0
stress is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
day 0
Stress
Periodo de tiempo: Month 3
stress is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
Month 3
Fatigue
Periodo de tiempo: Day 0
Fatigue is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
Day 0
Fatigue
Periodo de tiempo: Month 3
Fatigue is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
Month 3
Sleep
Periodo de tiempo: day 0
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
day 0
Sleep
Periodo de tiempo: Month 3
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
Month 3
Burnout
Periodo de tiempo: day 0
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
day 0
Burnout
Periodo de tiempo: Month 3
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
Month 3
Mindfulness
Periodo de tiempo: Day 0
Midfuless is assessed by the Freiburg Mindfulness Inventory-14 (FMI) composed by a 4-point Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree)
Day 0
Mindfulness
Periodo de tiempo: Month 3
Midfuless is assessed by the Freiburg Mindfulness Inventory-14 (FMI) composed by a 4-point Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree)
Month 3
Coping
Periodo de tiempo: Day 0
Coping is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by an 11-point scale
Day 0
Coping
Periodo de tiempo: Month 3
Coping is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by an 11-point scale
Month 3
Emotions
Periodo de tiempo: Day 0
Emotions are assessed by the Emotion Régulation Questionnaire (ERQ) composed by 10 items on a 7-point likert scale ranging from 1 (strongly disagree) to 7 (strongly agree)
Day 0
Emotions
Periodo de tiempo: Month 3
Emotions are assessed by the Emotion Régulation Questionnaire (ERQ) composed by 10 items on a 7-point likert scale ranging from 1 (strongly disagree) to 7 (strongly agree)
Month 3
Perception of work
Periodo de tiempo: Day 0
Work perception is assessed by the Job Demand-Control-Support (JDSC) questionnaire of Karasek composed by 26 items on a 4-point scale ranging from 1 (strongly disagree) to 4 (strongly agree). It is also evaluated by the effort-reward imbalance model (ERI) of Siegrist composed by 46 items on a 5-point scale ranging from 1 (no agreement) to 5 (agree and very disturb).
Day 0
Perception of work
Periodo de tiempo: Month 3
Work perception is assessed by the Job Demand-Control-Support (JDSC) questionnaire of Karasek composed by 26 items on a 4-point scale ranging from 1 (strongly disagree) to 4 (strongly agree). It is also evaluated by the effort-reward imbalance model (ERI) of Siegrist composed by 46 items on a 5-point scale ranging from 1 (no agreement) to 5 (agree and very disturb).
Month 3
Self-efficacy
Periodo de tiempo: Day 0
Self-efficacy is assessed by the perceived self-efficacy scale composed by 10 items on a 4-point scale
Day 0
Self-efficacy
Periodo de tiempo: Month 3
Self-efficacy is assessed by the perceived self-efficacy scale composed by 10 items on a 4-point scale
Month 3
Alexithymia
Periodo de tiempo: Day 0
Alexithymia is assessed by the Twenty-item Toronto Alexithymia Scale (TAS20) composed by a 5-point scale from "strongly agree" to "strongly disagree".
Day 0
Alexithymia
Periodo de tiempo: Month 3
Alexithymia is assessed by the Twenty-item Toronto Alexithymia Scale (TAS20) composed by a 5-point scale from "strongly agree" to "strongly disagree".
Month 3
Illness perception
Periodo de tiempo: Day 0
Perception of illness is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by a 11-point scale.
Day 0
Illness perception
Periodo de tiempo: Month 3
Perception of illness is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by a 11-point scale.
Month 3
Metacognition
Periodo de tiempo: Day 0
Metacognition is assessed by the MetaCognition Questionnaire (MCQ-30) composed by 30 items on a 5-point scale
Day 0
Metacognition
Periodo de tiempo: Month 3
Metacognition is assessed by the MetaCognition Questionnaire (MCQ-30) composed by 30 items on a 5-point scale
Month 3
Time perception
Periodo de tiempo: Day 0
Perception of the time is assessed by the Metacognitive questionnaire on time perception (MQT) composed by 24 items on a 5-point scale. It is also evaluated by the Zimbardo Time Perspective Inventory (ZPTI) composed by 56 items on a 5-point scale from "very uncharacteristic" to "very characteristic".
Day 0
Time perception
Periodo de tiempo: Month 3
Perception of the time is assessed by the Metacognitive questionnaire on time perception (MQT) composed by 24 items on a 5-point scale. It is also evaluated by the Zimbardo Time Perspective Inventory (ZPTI) composed by 56 items on a 5-point scale from "very uncharacteristic" to "very characteristic".
Month 3
Physical activity
Periodo de tiempo: Day 0
Physical activity is assessed by the Recent Physical Activity Questionnaire (RPAQ)
Day 0
Physical activity
Periodo de tiempo: Month 3
Physical activity is assessed by the Recent Physical Activity Questionnaire (RPAQ)
Month 3
Life style
Periodo de tiempo: Day 0
life style is assessed with a questionnaire on coffee consumption, food intake, etc
Day 0
Life style
Periodo de tiempo: Month 3
life style is assessed with a questionnaire on coffee consumption, food intake, etc
Month 3
cholesterol
Periodo de tiempo: Day 0
measure by blood analyses to evaluate alloplastic load
Day 0
triglycerides
Periodo de tiempo: Day 0
measure by blood analyses to evaluate alloplastic load
Day 0
cholesterol
Periodo de tiempo: Month 3
measure by blood analyses to evaluate alloplastic load
Month 3
triglycerides
Periodo de tiempo: Month 3
measure by blood analyses to evaluate alloplastic load
Month 3
Cortisol
Periodo de tiempo: Day 0
hormone measure by blood analyses to evaluate alloplastic load
Day 0
Cortisol
Periodo de tiempo: Month 3
hormone measure by blood analyses to evaluate alloplastic load
Month 3
DHEAS
Periodo de tiempo: day 0
hormone measure by blood analyses to evaluate alloplastic load
day 0
DHEAS
Periodo de tiempo: Month 3
hormone measure by blood analyses to evaluate alloplastic load
Month 3
BDNF
Periodo de tiempo: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
BDNF
Periodo de tiempo: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
CRP
Periodo de tiempo: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
pro-inflammatory cytokines
Periodo de tiempo: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
TNF alpha
Periodo de tiempo: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
CRP
Periodo de tiempo: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
pro-inflammatory cytokines
Periodo de tiempo: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
TNF alpha
Periodo de tiempo: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
NPY
Periodo de tiempo: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
NPY
Periodo de tiempo: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
Leptin
Periodo de tiempo: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Leptin
Periodo de tiempo: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
Ghrelin
Periodo de tiempo: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Ghrelin
Periodo de tiempo: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
NPY
Periodo de tiempo: day 0
measure by blood analyses to evaluate appetite regulation
day 0
NPY
Periodo de tiempo: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
adiponectine
Periodo de tiempo: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
adiponectine
Periodo de tiempo: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
CCK
Periodo de tiempo: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Month 3
Periodo de tiempo: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Insulin
Periodo de tiempo: Day 0
measure by blood analyses to evaluate glucid metabolism
Day 0
Insulin
Periodo de tiempo: Month 3
measure by blood analyses to evaluate glucid metabolism
Month 3
HbA1c
Periodo de tiempo: Day 0
measure by blood analyses to evaluate glucid metabolism
Day 0
HbA1c
Periodo de tiempo: Month 3
measure by blood analyses to evaluate glucid metabolism
Month 3
glucose
Periodo de tiempo: Day 0
measure by blood analyses to evaluate glucid metabolism
Day 0
glucose
Periodo de tiempo: Month 3
measure by blood analyses to evaluate glucid metabolism
Month 3
Albumin
Periodo de tiempo: Day 0
measure by blood analyses to evaluate protid metabolism
Day 0
Albumin
Periodo de tiempo: Month 3
measure by blood analyses to evaluate protid metabolism
Month 3
transthyretin
Periodo de tiempo: Day 0
measure by blood analyses to evaluate protid metabolism
Day 0
transthyretin
Periodo de tiempo: Month 3
measure by blood analyses to evaluate protid metabolism
Month 3
Homeostasis
Periodo de tiempo: Day 0
measure of Fibroblast growth factor 23 (FGF23) by blood analyses to evaluate bone metabolism
Day 0
Homeostasis
Periodo de tiempo: Month 3
measure of Fibroblast growth factor 23 (FGF23) by blood analyses to evaluate bone metabolism
Month 3
Osteoresorption
Periodo de tiempo: Day 0
measure of C-terminal Telopeptide of Type I collagen (CTx) by blood analyses to evaluate bone metabolism
Day 0
Osteoresorption
Periodo de tiempo: Month 3
measure of C-terminal Telopeptide of Type I collagen (CTx) by blood analyses to evaluate bone metabolism
Month 3
Osteoformation
Periodo de tiempo: Day 0
measure of decarboxylated osteocalcine and BSAP by blood analyses to evaluate bone metabolism
Day 0
Osteoformation
Periodo de tiempo: Month 3
measure of decarboxylated osteocalcine and BSAP by blood analyses to evaluate bone metabolism
Month 3
VEGF
Periodo de tiempo: Day 0
measure by blood analyses to evaluate cardiovascular function
Day 0
VEGF
Periodo de tiempo: Month 3
measure by blood analyses to evaluate cardiovascular function
Month 3
PAI1
Periodo de tiempo: Day 0
measure by blood analyses to evaluate cardiovascular function
Day 0
PAI1
Periodo de tiempo: Month 3
measure by blood analyses to evaluate cardiovascular function
Month 3
weight
Periodo de tiempo: Day 0
measure of weight in kilograms
Day 0
weight
Periodo de tiempo: Month 3
measure of weight in kilograms
Month 3
waist circumference
Periodo de tiempo: Day 0
measure of waist circumference in centimetres
Day 0
waist circumference
Periodo de tiempo: Month 3
measure of waist circumference in centimetres
Month 3

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Anticipado)

1 de septiembre de 2020

Finalización primaria (Anticipado)

1 de junio de 2021

Finalización del estudio (Anticipado)

1 de junio de 2021

Fechas de registro del estudio

Enviado por primera vez

10 de febrero de 2020

Primero enviado que cumplió con los criterios de control de calidad

13 de marzo de 2020

Publicado por primera vez (Actual)

17 de marzo de 2020

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

17 de marzo de 2020

Última actualización enviada que cumplió con los criterios de control de calidad

13 de marzo de 2020

Última verificación

1 de febrero de 2020

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • RBHP 2019 DUTHEIL
  • 2019-A01804-53 (Otro identificador: ANSM)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

Indeciso

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

3
Suscribir